Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
study ends around

Description

Summary

Official Title

A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

Keywords

Hepatocellular Carcinoma, Lenvatinib, Sorafenib, Livmoniplimab, Budigalimab, ABBV-181, ABBV-151, Cancer, Carcinoma

Eligibility

Locations

  • University of California, Los Angeles /ID# 253292
    Los Angeles California 90095 United States
  • UC Irvine /ID# 252707
    Orange California 92868 United States
  • California Pacific Medical Center - San Francisco - Webster Street /ID# 253291
    San Francisco California 94115 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Related Info.
ID
NCT05822752
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 130 people participating
Last Updated